Dear Reader,

As we approach the end of 2016, and publish our final issue of Drugs & Therapy Perspectives for the year, I wish to reflect on another successful year for the journal and for others in the Adis Premier journal portfolio, and to thank all who have contributed to Drugs & Therapy Perspectives over the past 12 months.

The past year has seen a substantial increase in the number of original research and other externally written articles being published in Drugs & Therapy Perspectives. Overall, this change appears to be a positive one, with many such articles being highly downloaded. Our in-house written Adis Drug Q&A articles and other article types also continue to popular with our readership. As of September 2016, Drugs & Therapy Perspectives’ top downloaded articles from SpringerLink this year included:

  • Castaldo RS. Switching statin-treated patients from fenofibrate to the prescription omega-3 therapy icosapent ethyl: a retrospective case series. Drugs Ther Perspect. 2016;32(4):162–9. doi:10.1007/s40267-016-0288-3

  • Whelan B, Musters E, Murray A., et al. Review of the home care programmes for respiratory syncytial virus (RSV) prophylaxis in Ireland and The Netherlands. Drugs Ther Perspect. 2016;32(3):119–30. doi:10.1007/s40267-015-0275-0

  • Cohen M, Stallone F, Pallin DJ. Injectable promethazine: a risky drug of questionable efficacy. Drugs Ther Perspect. 2016;32(7):294–6. doi:10.1007/s40267-016-0296-3

  • K.A. Lyseng-Williamson. Vedolizumab in moderately to severely active ulcerative colitis or Crohn’s disease: a guide to its use. Drugs Ther Perspect. 2016;32(7):265–75. doi:10.1007/s40267-016-0311-8

  • Adis Medical Writers. Effective treatment of attention-deficit hyperactivity disorder also helps control symptoms of comorbid oppositional defiant disorder. Drugs Ther Perspect. 2016;32(3):104–9. doi:10.1007/s40267-015-0269-y

  • Adis Medical Writers. Stevens–Johnson syndrome and toxic epidermal necrolysis: early recognition and prompt management may reduce mortality. Drugs Ther Perspect. 2016;32(6):238–43. doi:10.1007/s40267-016-0294-5

  • Behr J, Lyseng-Williamson KA. Ambrisentan in pulmonary arterial hypertension: a guide to its use in the EU. Drugs Ther Perspect. 2016;32(2):50–9. doi:10.1007/s40267-015-0273-2

  • Adis Medical Writers. Beware of hepatotoxicity risk with new oral anticoagulants (NOACs). Drugs Ther Perspect. 2016;32(3):113–8. doi:10.1007/s40267-015-0274-1

  • Shirley M, McCormack PL. Radium-223 dichloride in castration-resistant prostate cancer with symptomatic bone metastases: a guide to its use. Drugs Ther Perspect. 2016;32(3):98–103. doi:10.1007/s40267-016-0283-8

  • Syed YY, Lyseng-Williamson KA, Blair HA, et al. Umeclidinium/vilanterol dry-powder inhaler in chronic obstructive pulmonary disease: a guide to its use in the EU. Drugs Ther Perspect. 2016;32(7):276–81. doi:10.1007/s40267-016-0309-2

I offer my sincere thanks to all authors who have contributed articles to Drugs & Therapy Perspectives over the course of 2016. Their skill and dedication are critical to the continued publication of the journal. The quality of published articles is, similarly, testament to the significant efforts of the peer reviewers, whose commitment ensures that the journal’s content is held to the highest possible standard.

I would like to thank the members of the journal’s Honorary Editorial Board, who have acted as peer reviewers and authors, and have provided guidance on journal content, policy and processes:

Darrell R. Abernethy, Silver Spring, MD, USA

Christopher P. Alderman, Adelaide, SA, Australia

Yusef A. Alomi, Riyadh, Saudi Arabia

Francisco Araujo, Seville, Spain

Mohamed Baraka, Damman, Saudi Arabia

Aygin Bayrakta-Ekincioglu, Ankara, Turkey

Gabriele Bianchi Porro, Milan, Italy

Margarida Caramona, Coimbra, Portugal

Margarida Castel-Branco, Coimbra, Portugal

Natalie Cebotarenco, Chişinău, Moldova

Surarong Chinwong, Chiang Mai, Thailand

Barbara Claus, Ghent, Belgium

Richard O. Day, Sydney, NSW, Australia

Isabel Vitoria Figueiredo, Coimbra, Portugal

William H. Frishman, Valhalla, NY, USA

David J. Greenblatt, Boston, MA, USA

Mara Guerreiro, Lisbon, Portugal

Martina Hahn, Eltville, Germany

Rob Janknegt, Sittard-Geleen, The Netherlands

Gail Judd, London, ON, Canada

Hannelore Kreckel, Giessen, Germany

Gert Laekeman, Leuven, Belgium

Michel Le Duff, Rennes, France

Micha Levy, Jerusalem, Israel

Howard I. Maibach, San Francisco, CA, USA

Petra Matoulková, Hradec Králové, Czech Republic

Audrey McAnaw, Dundee, Scotland

Tadja Miharija-Gala, Ljubljana, Slovenia

Sanja Mirkov, Melbourne, VIC, Australia

Emina Obarcanin, Düsseldorf, Germany

Gurumurthi Parthasarathi, Mysore, India

Sandeep Saluja, Agra, India

Jerome Schentag, Buffalo, NY, USA

Rima Bharatbhai Shah, India

Kirsten K. Viktil, Oslo, Norway

In addition, I would like to thank the following individuals who also acted as reviewers for articles published in the 2016 issues of Drugs & Therapy Perspectives:

Elisabetta Abruzzese, Italy

Alice Acurado, Portugal

A. Deniz Akkaya, Turkey

Emanuele Angelucci, Italy

Yusi Anggriani, Indonesia

Alessandro Antonelli, Italy

Angelo Antonini, Italy

Sabina A. Antoniu, Romania

Venkata S. Atluri, USA

Michele Baccarani, Italy

Harold E. Bays, USA

Meral Beksac, Turkey

Karl-Christian Bergmann, Germany

Lothar Bergmann, Germany

Lise Bernard, France

Daniel G. Bichet, Canada

John E. A. Blair, USA

Corradi Blandizzi, Italy

Bernd Bokemeyer, Germany

Alessandro Borghi, Italy

Ambrogio Bottoni, Italy

Murat Bozlu, Turkey

J. Christopher Bradberry, USA

Marta Benedetta Brumana, Italy

Ana C. Calvo, Spain

Giancarlo Castaman, Italy

Renato Caviglia, Italy

Yuksel Cavusoglu, Turkey

Soju Chang, USA

Jing Chen, China

Luis Costa, Portugal

Phillip Couratier, France

Jordan R. Covvey, USA

Tine L. M. De Backer, Belgium

Javier de la Rubia, Spain

Ronan Desmond, Ireland

Tobias Dreischulte, UK

Gregory Duncan, Australia

Steven R. Feldman, USA

Maria Teresa Ferreira Herdeiro, Portugal

Richard G. Fiscella, USA

Anthony W. Fox, UK

Pierre Fumoleau, France

Bharat Gajjar, India

Arthur F. Gelb, USA

Jalal K. Ghali, USA

Clara E. Green, UK

Fabrizio Guarneri, Italy

Yoshiyuki Hamamoto, Japan

Khedidja Hedna, Sweden

Wayne J.G. Hellstrom, USA

Nusrat Homaira, Australia

Friedrich Horak, Austria

Catherine Hurt, UK

Cristoforo Incorvaia, Italy

John K. Iskander, USA

Edward M. Kerwin, USA

Leon H. Kircik, USA

Eija Kivekas, Finland

Richard Kones, USA

Ines Krass, Australia

Anne Lee, UK

Theresa Leung, Hong Kong

Steven J. Lichtenstein, USA

Hua Ling, USA

José Lopes, Portugal

Giovanni Maconi, Italy

Slawomir Majewski, Poland

Louise Mallet, Canada

Pier Mannuccio Mannucci, Italy

Juan Antonio Martinez Tadeo, Spain

Ana Paula Martins, Portugal

Maria-Victoria Mateos, Spain

Cormac McCarthy, USA

Hideaki Miyoshi, Japan

Anish Nadkarni, USA

Steve E. Nissen, USA

Dag Nyholm, Sweden

Sven-Eric Olsson, Sweden

Arnold P. Oranje, The Netherlands

Clive Page, UK

Farzad Peiravian, Iran

Marek Petras, Czech Republic

Andrea Prodi, Italy

Margaret V. Ragni, USA

Hesty Utami Ramadaniati, Indonesia

Helena Ribeiro, Portugal

Yoshifumi Saisho, Japan

Sujit Vijay Sakpal, USA

Mohammad Saleem, USA

Salvatore Salomone, Italy

Phillip Scheinberg, USA

Ignacio Segarra, Spain

Bruno Sepodes, Portugal

Amit M. Shah, India

Margaret Sheridan-Pereira, Ireland

Gopendra Singh, India

Cassian Sitaru, Germany

Dirk D. Skowasch, Germany

Malcom Steiger, UK

Robert A. Stockley, UK

Maysa Suyagh, Jordan

Andrzej Robert Tomasik, Poland

Thomas E. Wessendorf, Germany

Faysal A. Yafi, USA

Masakazu Yamada, Japan

Nazia Yasmeen, India

Yildiray Yeniay, Turkey

Robin J.Young, UK

Chao Zhou, The Netherlands

In other portfolio news, the release of the ISI Journal Citation Reports in mid-2016 saw a rise in impact factor against the previous year for the majority of our ISI-indexed journals. Most notably, five of our journals saw an increase of over 10% in impact factor—The Patient (17.08%), Clinical Drug Investigation (15.99%), the American Journal of Clinical Dermatology (13.17% increase), Drug Safety (12.52%), and Drugs (12.43%).

Another important milestone was reached for our recently launched open access journals, Drug Safety–Case Reports and Drugs–Real World Outcomes. Content from these journals is now available on PubMed Central.

The Adis journals portfolio will expand in 2017, with the launch of PharmacoEconomics–Open. This new journal will be fully open access and will focus on the publication of applied research on the economic implications and health outcomes associated with drugs, devices and other healthcare interventions. It joins our other well respected health outcomes publications, PharmacoEconomics, Applied Health Economics & Health Policy and The Patient: Patient Centered Outcomes Research.

I hope that you have found the articles published throughout 2016 to be both interesting and informative. I have appreciated the high quality of content contributed to the journal this year and look forward to keeping you up to date with topical issues related to rational drug use and disease management in the clinical practice setting in 2017.

With best wishes,

Katherine Lyseng-Williamson